Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | FADS1 | O60427 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8799124 | 0.77 | MAOA (0.40) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL10449393 | 0.77 | MAOA (0.42) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL16762286 | 0.74 | MAOA (0.36) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL6949814 | 0.74 | MAOA (0.38) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL6921642 | 0.74 | MAOA (0.38) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL4429415 | 0.72 | PAX8 (0.48) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL2359630 | 0.72 | TSHR (0.47) | CYP3A4TSHR | |
| SCHEMBL4415644 | 0.72 | CYP3A4 (0.42) | DYRK1AMAOAMAOBFTONFKB1 | |
| SCHEMBL31238945 | 0.70 | TSHR (0.41) | CYP3A4TSHR | |
| SCHEMBL11880529 | 0.70 | TSHR (0.41) | CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | DYRK1A 2344/4885MAOA 1001/4885MAOB 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.